Label: information for the user
AZOPT 10 mg/ml eye drop suspension
brinzolamide
Read this label carefully before starting to use this medication,because it contains important information for you.
-Keep this label, as you may need to read it again.
-If you have any questions, consult your doctor or pharmacist.
-This medication has been prescribed only for you, and you should not give it to others even if they have the same symptoms as you, as it may harm them.
-If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this label. See section 4.
1.What AZOPT is and for what it is used
2.What you need to know before starting to use AZOPT
3.How to use AZOPT
4.Possible adverse effects
5.Storage of AZOPT
6.Contents of the package and additional information
AZOPT contains brinzolamide which belongs to a group of medicines called carbonic anhydrase inhibitors and reduces the pressure inside the eye.
AZOPT eye drops are used to treat high eye pressure. This pressure may lead to a disease called glaucoma.
If the pressure in the eye is too high, it may damage your vision.
No use AZOPT
-If you have severe kidney problems.
-If you are allergic to brinzolamide or to any of the other ingredients of this medication (listed in section 6).
-If you are allergic to a group of medicines called sulfonamides. Examples: medicines used to treat diabetes and infections, and also diuretics (tablets to urinate). AZOPT could cause the same allergy.
-If you have too much acid in your blood (a condition called hyperchloremic acidosis).
If you have any doubts, consult your doctor.
Warnings and precautions
Consult your doctor or pharmacist before starting to use AZOPT:
-If you have kidney or liver problems.
-If you have dry eye or corneal problems.
-If you are using other medicines that contain sulfonamides.
-If you have a specific type of glaucoma where the pressure inside the eye increases due to deposits that block the drainage of fluid in the eye (pseudoexfoliative glaucoma or pigmentary glaucoma) or a specific type of glaucoma where the pressure inside the eye increases (sometimes rapidly) due to a bulging towards the front of the eye that blocks the drainage of fluid (narrow-angle glaucoma).
-If you have ever developed a severe skin rash or skin peeling, blisters, and/or mouth sores after using AZOPT or other related medicines.
Be especially careful with AZOPT:
Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported in association with brinzolamide treatment. Stop using AZOPT and seek medical attention immediately if you notice any of the symptoms related to these severe skin reactions described in section 4.
Children and adolescents
AZOPT should not be used in infants, children, and adolescents under 18 years old, unless your doctor recommends it.
Other medicines and AZOPT
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medicine, including those purchased without a prescription.
Consult your doctor if you are using another carbonic anhydrase inhibitor (acetazolamide or dorzolamide, see section 1 What is AZOPT and what is it used for).
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Women of childbearing potential should use effective contraceptive methods during treatment with AZOPT. AZOPT is not recommended during pregnancy or breastfeeding. Do not use AZOPT unless clearly indicated by your doctor.
Consult your doctor or pharmacist before using any medicine.
Driving and operating machinery
Do not drive or operate machinery until your vision is clear. Immediately after applying AZOPT, you may notice that your vision becomes blurry.
AZOPT may impair your ability to perform tasks that require mental sharpness and/or physical coordination. If you notice these effects, be careful when driving or operating machinery.
AZOPT contains benzalkonium chloride
This medicine contains 3.35 µg of benzalkonium chloride per drop (= 1 dose), equivalent to 0.01% or 0.1 mg/ml.
AZOPT contains a preservative (benzalkonium chloride) that can be absorbed by soft contact lenses and may alter the color of contact lenses. Remove contact lenses before using this medicine and wait 15 minutes before reinserting them. Benzalkonium chloride may cause eye irritation, especially if you have dry eye or other corneal diseases (transparent layer at the front of the eye). Consult your doctor if you feel a strange sensation, burning, or pain in the eye after using this medicine.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Use AZOPT only in your eye(s). Do not swallow or inject.
The recommended dose is1drop in the affected eye(s) two times a day‑in the morning and at night.
This is the dosage you should follow unless your doctor has indicated otherwise. AZOPT should only be applied in both eyes if your doctor has recommended it. Follow the treatment for the entire period of time indicated by your doctor.
How to use
123
If a drop falls outside the eye, try again.
If you are using another eye drop, wait at least 5minutes between the application of AZOPT and the other drops. Eye ointments should be administered last.
If you use more AZOPT than you should
If too much has been applied, you can remove it by washing your eyes with warm water. Do not apply more drops until it is time for the next dose.
If you forgot to use AZOPT
Apply a drop as soon as you remember and then continue with your regular treatment schedule. Do not apply a double dose to compensate for the missed dose.
If you interrupt the treatment with AZOPT
If you stop using AZOPT without consulting your doctor, the pressure in your eye will not be controlled, which could cause vision loss.
Like all medicines, this medicine may causeside effects,although not everyone will experience them.
The following side effects have been observed with AZOPT.
Stop using AZOPT and seek medical attention immediately if you notice any of the following symptoms:
•flat red spots, in the shape of a target or circles on the trunk, often with central blisters, skin peeling, mouth ulcers, throat, nose, genital, and eye ulcers. These severe skin eruptions may be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).
Frequent(may affect up to 1 in 10 people)
Infrequent(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 10,000 people)
Frequency unknown(cannot be estimated from available data)
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in theAnnex V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the bottle and on the box after “CAD”. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
To prevent infections,you must discard each bottle four weeks after opening it for the first time.Note the opening date of each bottle in the space below and on the label of the bottle and the box. In the packaging that only contains one bottle, note only one date.
Opening date (1):
Opening date (2):
Opening date (3):
Medications should not be thrown down the drain or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you do not need. In this way, you will help protect the environment.
Composition of AZOPT
Appearance of the product and contents of the package
AZOPT is a milky liquid (suspension) that is presented in a box containing a 5 ml or 10 ml plastic bottle with a screw cap, or in a box containing three 5 ml plastic bottles with screw caps. Only some package sizes may be marketed.
Holder of the marketing authorization
Marketing authorization holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Responsible for manufacturing
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany
Novartis Manufacturing NV
Rijksweg 14
2870 Puurs-Sint-Amands
Belgium
Novartis Farmacéutica, S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Siegfried El Masnou, S.A.
Camil Fabra 58
El Masnou
08320 Barcelona
Spain
Sophie-Germain-Strasse 10
90443 Nürnberg
Germany
To obtain more information about this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 | Lietuva Novartis Pharma Services Inc. Tel: +370 5 269 16 50 | |
Novartis Pharma Services Inc. ???: +359 2 489 98 28 | Luxembourg/Luxemburg Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 | |
Ceská republika Novartis s.r.o. Tel: +420 225 775 111 | Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00 | |
Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: +356 2122 2872 | |
Deutschland Novartis Pharma GmbH Tel: +49 911 273 0 | Nederland Novartis Pharma B.V. Tel: +31 26 37 82 111 | |
Eesti Novartis Pharma Services Inc. Tel: +372 66 30 810 | Norge Novartis Norge AS Tlf: +47 23 05 20 00 | |
Ελλ?δα Novartis (Hellas) A.E.B.E. Τηλ: +30 210 281 17 12 | Österreich Novartis Pharma GmbH Tel: +43 1 86 6570 | |
España Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4888 | |
France Novartis Pharma S.A.S. Tél: +33 1 55 47 66 00 | Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 | |
Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 220 | România Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 | |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 50 | |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Novartis Slovakia s.r.o. Tel: + 421 2 5542 5439 | |
Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133 200 | |
Κ?προς Novartis Pharma Services Inc. Τηλ: +357 22 690 690 | Sverige Novartis Sverige AB Tel: +46 8 732 32 00 | |
Latvija Novartis Pharma Services Inc. Tel: +371 67 887 070 |
Last update of the summary of product characteristics
For detailed information about this medicinal product, please visit the website of the European Medicines Agency:
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.